SLN earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -2.74. Updated 2026-07-23.
Silence Therapeutics (SLN) Research Hub
Silence Therapeutics (SLN) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 19.78 USD (+0.56%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.74, market cap 0.54B. This hub links to the full technical, earnings and options research available for SLN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 19.78 USD (+0.56%) |
| 52-week range | 6.61 USD – 19.86 USD |
| Trend regime | Range |
| 14-day RSI | 85.8 (Overbought) |
| Trailing P/E | -2.74 |
| Market cap | 0.54B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for SLN
Covered Call on SLN: how it works, illustrative setup around the real 19.78 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SLN: how it works, illustrative setup around the real 19.78 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SLN: how it works, illustrative setup around the real 19.78 USD price, max profit/loss, breakeven and when to use it. Educational.
SLN technical analysis: range, last 19.78 USD, RSI 85.8, 52w range 6.61 USD–19.86 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SLN in?
Silence Therapeutics (SLN) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is SLN in an uptrend or downtrend?
As of 2026-10-26, SLN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SLN's trailing P/E ratio?
SLN's trailing P/E is -2.74, with a market cap of 0.54B. See the earnings research page for full valuation detail.
When does SLN next report earnings?
SLN is next scheduled to report earnings on 2026-08-06.